[Canesten (clotrimazole) in the treatment of vulvovaginal moniliasis]. 1980

J Bagdaszewska-Czabanowska, and E Wiehler

UI MeSH Term Description Entries
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002176 Candida albicans A unicellular budding fungus which is the principal pathogenic species causing CANDIDIASIS (moniliasis). Candida albicans var. stellatoidea,Candida stellatoidea,Dematium albicans,Monilia albicans,Myceloblastanon albicans,Mycotorula albicans,Parasaccharomyces albicans,Procandida albicans,Procandida stellatoidea,Saccharomyces albicans,Syringospora albicans
D002181 Candidiasis, Vulvovaginal Infection of the VULVA and VAGINA with a fungus of the genus CANDIDA. Moniliasis, Vulvovaginal,Vaginitis, Monilial,Candidiasis, Genital,Genital Vulvovaginal Candidiasis,Vaginal Yeast Infection,Vaginal Yeast Infections,Candidiasis, Genital Vulvovaginal,Genital Candidiasis,Infection, Vaginal Yeast,Infections, Vaginal Yeast,Monilial Vaginitis,Vulvovaginal Candidiasis,Vulvovaginal Candidiasis, Genital,Vulvovaginal Moniliasis,Yeast Infection, Vaginal,Yeast Infections, Vaginal
D003022 Clotrimazole An imidazole derivative with a broad spectrum of antimycotic activity. It inhibits biosynthesis of the sterol ergostol, an important component of fungal CELL MEMBRANES. Its action leads to increased membrane permeability and apparent disruption of enzyme systems bound to the membrane. Bay b 5097,Canesten,FB b 5097,Kanesten,Klotrimazole,Lotrimin,Mycelex
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013488 Suppositories Medicated dosage forms that are designed to be inserted into the rectal, vaginal, or urethral orifice of the body for absorption. Generally, the active ingredients are packaged in dosage forms containing fatty bases such as cocoa butter, hydrogenated oil, or glycerogelatin that are solid at room temperature but melt or dissolve at body temperature. Rectal Suppositories,Vaginal Suppositories,Vaginal Suppository,Suppositories, Rectal,Suppositories, Vaginal,Suppository, Vaginal
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

J Bagdaszewska-Czabanowska, and E Wiehler
July 1976, Die Medizinische Welt,
J Bagdaszewska-Czabanowska, and E Wiehler
January 1982, Ginekologia polska,
J Bagdaszewska-Czabanowska, and E Wiehler
May 1978, Fel'dsher i akusherka,
J Bagdaszewska-Czabanowska, and E Wiehler
May 1950, American journal of obstetrics and gynecology,
J Bagdaszewska-Czabanowska, and E Wiehler
October 1955, Obstetricia y ginecologia latino-americanas,
J Bagdaszewska-Czabanowska, and E Wiehler
August 1957, Quaderni di clinica ostetrica e ginecologica,
J Bagdaszewska-Czabanowska, and E Wiehler
May 1979, Polski tygodnik lekarski (Warsaw, Poland : 1960),
J Bagdaszewska-Czabanowska, and E Wiehler
January 1976, Sovetskaia meditsina,
J Bagdaszewska-Czabanowska, and E Wiehler
March 2013, Iranian journal of microbiology,
J Bagdaszewska-Czabanowska, and E Wiehler
January 1977, La Prensa medica mexicana,
Copied contents to your clipboard!